As of May, 8 Adamas Pharmaceuticals, Inc. (ADMS) Analysts See $-1.32 EPS

April 16, 2018 - By Jenna Rose

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Corporate Logo

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is awaited to publish earnings on May, 8., according to Faxor. Analysts forecast $-1.32 EPS, which is $0.60 down or 83.33 % from 2017’s $-0.72 EPS. Wall Street sees 3.94 % negative EPS growth as of May, 8. On during the last trading session the stock increased $0.26 or 1.08%, reaching $24.37.Adamas Pharmaceuticals, Inc. has volume of 201,378 shares. Since April 16, 2017 ADMS has risen 35.83% and is uptrending. ADMS outperformed by 24.28% the S&P500.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Total analysts of 8 have positions in Adamas Pharmaceuticals (NASDAQ:ADMS) as follows: 8 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 30, 2017 according to StockzIntelligence Inc Adamas Pharmaceuticals has 13 analyst reports. In Tuesday, January 30 report Piper Jaffray maintained the stock with “Buy” rating. On Wednesday, November 8 Noble Financial maintained the shares of ADMS in report with “Buy” rating. On Friday, November 3 the company was maintained by Mizuho. On Friday, March 9 the rating was maintained by Mizuho with “Buy”. On Tuesday, February 20 the firm has “Buy” rating by Evercore given. On Tuesday, February 20 the firm has “Buy” rating by Mizuho given. On Wednesday, November 29 Northland Capital initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) with “Buy” rating. On Tuesday, January 23 the firm has “Buy” rating given by Mizuho. On Wednesday, April 4 the company was initiated by Leerink Swann. On Thursday, February 22 the stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Piper Jaffray.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders.The firm is worth $653.29 million. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.Currently it has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: